KUALA LUMPUR (May 28): Pharmaniaga Bhd was up by as much as 20 sen or 4.18% in morning trade today, after Sinovac Biotech Ltd affirmed yesterday that it is the sole distributor of its Covid-19 vaccine in Malaysia, in fill-and-finish and finished forms.
At 10.15am, the counter pared some gains to settle 19 sen or 3.97% higher at RM4.98, giving it a market capitalisation of RM1.25 billion.
It was the seventh top gainer on the local bourse.
Yesterday, Sinovac’s chief business officer Helen Yang said it enjoys a very good working relationship with Pharmaniaga.
“We are dealing with Pharmaniaga through a government-to-government arrangement, without any involvement of other third parties.
“We have been meeting each other’s obligations and all contractual deliveries are on schedule,” she said.
Sinovac, along with Pfizer and AstraZeneca, is one of three brands of Covid-19 vaccines currently available through Malaysia’s National Immunisation Programme (PICK).
Pharmaniaga has received a million doses of the finished vaccine from Sinovac, and plans to import a further 10 million doses of the finished vaccine from China.
It expects to supply a total of 8.6 million doses of the Sinovac Covid-19 vaccine by the end of June.
Read also:
Sinovac confirms Pharmaniaga its sole vaccine distributor in Malaysia
